NCT05594745 is a Phase 4 clinical trial of Lifitegrast Ophthalmic in Dry Eye Syndromes, sponsored by Tauber Eye Center.

Who is sponsoring NCT05594745?

NCT05594745 is sponsored by Tauber Eye Center.

What drugs are being tested in NCT05594745?

Interventions in NCT05594745: Lifitegrast Ophthalmic, Systane Free, Lipiflow.

What condition does NCT05594745 study?

NCT05594745 studies Dry Eye Syndromes.

Is NCT05594745 still recruiting?

NCT05594745 is currently completed. Last updated 12 April 2023.

Last reviewed 2023-04-12 · How we verify

NCT05594745

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment Regimens in Meibomian Gland Dysfunction

Completed Phase 4 Last updated 12 April 2023

What this trial tests

Phase 4 trial testing Lifitegrast Ophthalmic in Dry Eye Syndromes in 60 participants. Completed in 21 January 2023.

Timeline

2 March 2021

Primary endpoint
21 January 2023

21 January 2023

Quick facts

Lead sponsor	Tauber Eye Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	60
Start date	2 March 2021
Primary completion	21 January 2023
Estimated completion	21 January 2023
Sites	1 location across United States

Drugs / interventions tested

Lifitegrast Ophthalmic — full drug profile →
Systane Free — full drug profile →
Lipiflow

Conditions studied

Dry Eye Syndromes — all drugs for Dry Eye Syndromes →

Sponsor

Tauber Eye Center — full company profile →

Who can join

Eligibility, any sex, with Dry Eye Syndromes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study seeks to explore the relevance of inflammation in dry eye patients with MGD and compare the efficacy of LipiFlow treatment followed by lid hygiene and lubricant treatment with Systane Ultra or LipiFlow treatment followed by lid hygiene and lifitegrast treatment in patients with meibomian gland dysfunction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Dry Eye Syndromes

Currently open trials in the same condition.

NCT07412860 — Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hy · NA · recruiting
NCT06913504 — Comparison Of Blue Light Filter Feature and Blue Blocking Lenses in Digital Device Users With Dry Eye Patients · NA · active not recruiting
NCT06913465 — The Impact of Hypothyroidism on Tear Production and Dry Eye Symptoms: Implications for Optometric Care · active not recruiting
NCT06831253 — Efficacy of Platelet-Rich Plasma Injection in Dry Eye Syndrome · NA · recruiting
NCT06220474 — Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD · NA · recruiting

Other Tauber Eye Center trials

Trials by the same sponsor.

NCT06317038 — To Evaluate the Performance of Total 30 (Lehifilcon A) Contact Lenses in Patients Using Digital Devices for Greater Than · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05594745 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tauber Eye Center
Last refreshed: 12 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05594745.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing